Hypertrophic and Keloid Scar Treatment Market projected to reach US$ 9,972.69 million by 2027 to grow at a CAGR of 10.6%

January 27 19:05 2021
The hypertrophic and keloid scar treatment market was valued at US$ 4,498.99 million in 2019 and is projected to reach US$ 9,972.69 million by 2027; it is expected to grow at a CAGR of 10.6% from 2020 to 2027.

Injuries and their extension deep into the dermis are the major cause of hypertrophic and keloids scars. Injuries can be further classified as scratches, burns, cuts, gashes, sutures, surgical incisions, and so on. The prevalence rate of injuries ultimately converting to a keloid or hypertrophic scars is 5–15%. In addition, skin conditions such as acne and dark pigmentation lead to hypertrophic and keloid scar development. The cases of different types of injuries are commonly seen among all age groups. Acne, sports injuries, and road accidents are more common among youngsters. Acne is also a common problem among middle-aged people, irrespective of their gender. The hormonal imbalance among people leads to acne, which might leave severe scars on skin. Acne is estimated to be affecting ~10% of the total global population. For instance, according to the American Academy of Dermatology Association, acne is the most common skin condition in the US, affecting ~50 million Americans annually. ~85% of people from the age group 12–24 experience minor acne problems. The changing lifestyle, habits, and increasing stress are widely contributing to acne problems. Therefore, the trend of treating scars caused by acne is much higher worldwide.

Advantages of laser treatment and increasing incidences of injuries are expected to drive the growth of market during the forecast period. However, the unavailability of universal treatment due to high costs, side effects, and scanty awareness hinder the market growth.

Request For Exclusive Sample PDF of this Report @ https://www.theinsightpartners.com/sample/TIPRE00007237/

Competitive Landscape hypertrophic and keloid scar treatment Market

Alliance Pharma plc; Mölnlycke HEALTH CARE AB.; Smith & Nephew; Newmedical Technology Inc.; Rejûvaskin; Sonoma Pharmaceuticals, Inc.; Suneva Medical; HRA Pharma; Lumenis, and Perrigo Company plc. are among the leading companies operating in the hypertrophic and keloid scar treatment market.

Based on scar type, the hypertrophic and keloid scar treatment market is bifurcated into hypertrophic and keloid. The hypertrophic segment held a larger share of the market in 2019, as hypertrophic scars are more common. Moreover, these scars do not grow outside the borders of the original wound and eventually grow smaller. Additionally, the treatment for hypertrophic scars typically requires non-invasive procedures such as gels, creams, and silicone sheets in the course of minor injuries and laser treatments. Thus, the segment is estimated to register a higher CAGR in the market during the forecast period.

According to the WHO data published in February 2020, road accident-led injuries are the leading cause of death among young adults aged 5–29. ~1.35 million fatalities are registered per year due to road accidents. However, the rate of severe injuries by road accidents is also rising. Therefore, the increasing number of accidents is indirectly leading to the rising demand for hypertrophic and keloid scar treatments.

In terms of product type, the hypertrophic and keloid scar treatment market is segmented into laser products, topical products, injectables, and other products. The injectables segment held the largest share of the market in 2019 and is estimated to register the highest CAGR in the market during the forecast period.

Based on end user, the hypertrophic and keloid scar treatment market is segmented into hospitals, clinics, and homecare. The hospitals segment held the largest share of the market in 2019 and is estimated to register the highest CAGR in the market during the forecast period.

At present, there are various treatments available to treat hypertrophic and keloid scars. The emerging treatments are based on stem cell therapy, verapamil, mitomycin C (MMC), interferons, bleomycin, ACE inhibitors, and botulinum toxin type A. Most of these treatments have shown promising results. On the other hand, the topical products are being used to reduce the thickness of scars and lighten them as they are esthetically unpleasing. However, laser treatment and radiotherapy are associated with side effects, and they do not heal the scars completely. Therefore, researchers are continuously studying these treatments and are yet to derive a standard treatment for hypertrophic and keloid scars. Likewise, manufacturers are engaged in developing products such as extracellular-matrix that control the proliferation of collagen, thereby preventing the excess deposition of the same. Keloid scars can also be related to genetic factors; hence, they are considered major clinical challenges. Therefore, the ongoing research and developments are likely to provide preventive measures and extraordinary treatments for hypertrophic and keloid scars treatment during the forecast period.

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Hypertrophic and Keloid Scar Treatment Market – By Scar Type
1.3.2 Hypertrophic and Keloid Scar Treatment Market – By Product Type
1.3.3 Hypertrophic and Keloid Scar Treatment Market – By End User
1.3.4 Hypertrophic and Keloid Scar Treatment Market – By Region
1.3.4.1 By Country

2. KEY TAKEAWAYS

3. RESEARCH METHODOLOGY

4. HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America – Pest Analysis
4.2.2 Europe – Pest Analysis
4.2.3 Asia-Pacific – Pest Analysis
4.2.4 Middle East and Africa – Pest Analysis
4.2.5 South and Central America – Pest Analysis
4.3. EXPERT OPINIONS

5. HYPERTROPHIC AND KELOID SCAR TREATMENT MARKET – KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS, RESTRAINTS & EXPECTED INFLUENCE OF COVID-19 PANDEMIC

Interested in Purchasing this Report? Click here @ https://www.theinsightpartners.com/buy/TIPRE00007237/

Note: If you have any special requirements, please let us know and we will offer you the report as you want.

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive and Defense.

Contact Us:

Call: +1-646-491-9876

Email: [email protected]

Media Contact
Company Name: The Insight Partners
Contact Person: Sameer Joshi
Email: Send Email
Phone: +1-646-491-9876
City: Pune
State: Maharashtra
Country: India
Website: https://www.theinsightpartners.com/


Warning: count(): Parameter must be an array or an object that implements Countable in /home/ghaziabadonline/dispurnewsflash.com/wp-content/themes/gadgetine-theme/includes/single/post-tags-categories.php on line 7